Abstract:Glioblastoma (GBM) is the most common type of malignant tumor of the central nervous system. The prognosis of patients with GBM is very poor, with a survival time of ~15 months. GBM is highly heterogeneous and highly aggressive. Surgical removal of intracranial tumors does provide a good advantage for patients as there is a high rate of recurrence. The understanding of this type of cancer needs to be strengthened, and the aim of the present study was to identify gene signatures present in GBM and uncover their potential mechanisms. The gene expression profiles of GSE15824 and GSE51062 were downloaded from the Gene Expression Omnibus database. Normalization of the data from primary GBM samples and normal samples in the two databases was conducted using R software. Then, joint analysis of the data was performed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the protein‑protein interaction (PPI) network of the differentially expressed genes (DEGs) was constructed using Cytoscape software. Identification of prognostic biomarkers was conducted using UALCAN. In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes. The top 1,000 upregulated DEGs and all of the downregulated DEGs were selected for GO, KEGG and prognostic biomarker analyses. The GO results showed that the upregulated DEGs were significantly enriched in biological processes (BP), including immune response, cell division and cell proliferation, and the downregulated DEGs were also significantly enriched in BP, including cell growth, intracellular signal transduction and signal transduction by protein phosphorylation. KEGG pathway analysis showed that the upregulated DEGs were enriched in circadian entrainment, cytokine‑cytokine receptor interaction and maturity onset diabetes of the young, while the downregulated DEGs were enriched in the TGF‑β signaling pathway, MAPK signaling pathway and pathways in cancer. All of the downregulated genes and the top 1,000 upregulated genes were selected to establish the PPI network, and the sub‑networks revealed that these genes were involved in significant pathways, including olfactory transduction, neuroactive ligand‑receptor interaction and viral carcinogenesis. In total, seven genes were identified as good prognostic biomarkers. In conclusion, the identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future.

Bioinformatic Analysis of Gene Expression and Methylation Regulation in Glioblastoma

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

Identification of glioblastoma-specific prognostic biomarkers via an integrative analysis of DNA methylation and gene expression

Integrative analysis of DNA methylation and gene expression profiles to identify biomarkers of glioblastoma

Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma.

DNA methylation in glioblastoma: impact on gene expression and clinical outcome

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.

Proteomic and Metabolomic Analyses Illustrate the Mechanisms of Expression of the O6-methylguanine-DNA Methyltransferase Gene in Glioblastoma

Retracted : Identification and validation of hypoxic markers of glioblastoma multiforme in methylation, somatic CNV characteristics based on large‐scale samples

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

Construction of Novel DNA Methylation-Based Prognostic Model to Predict Survival in Glioblastoma

Identification of Methylation Immune Subtypes and Establishment of a Prognostic Signature for Gliomas Using Immune-Related Genes

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Integrated Analysis to Evaluate the Prognostic Value of Signature Mrnas in Glioblastoma Multiforme

Identification of Core Differentially Methylated Genes in Glioma.

Screening of differentially expressed genes associated with human glioblastoma and functional analysis using a DNA microarray.

Bioinformatic Profiling Identifies an Immune-Related Risk Signature for Glioblastoma.

Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.

Identification of prognostic-related methylation-regulated differentially expressed genes in glioma based on bioinformatics analysis